{ "resourceType" : "Group", "id" : "189713", "meta" : { "versionId" : "3", "lastUpdated" : "2026-08-05T07:33:36.353Z" }, "language" : "en", "text" : { "status" : "extensions", "div" : "

Generated Narrative: Group 189713

version: 3; Last updated: 2026-08-05 07:33:36+0000

ArtifactPublicationStatus: Active

Artifact Author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:

CiteAs:

NCT04401202 Eligibility Criteria [Database Entry: FHIR Group Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 189713. Revised 2026-08-05. Available at: https://fevir.net/resources/Group/189713. Computable resource at: https://fevir.net/resources/Group/189713#json.

\n

url: https://fevir.net/resources/Group/189713

identifier: FEvIR Object Identifier/189713, FEvIR Linking Identifier/NCT04401202 Eligibility Criteria

name: NCT04401202_Eligibility_Criteria

title: NCT04401202 Eligibility Criteria

status: Active

publisher: Computable Publishing LLC

contact: support@computablepublishing.com

description:

Inclusion Criteria:

\n\n

copyright:

Copyright the Authors else Computable Publishing LLC. Noncommercial use permitted with CC BY-NC-SA 4.0 (https://creativecommons.org/licenses/by-nc-sa/4.0/). Commercial use permitted as agreed in Terms of Use (https://fevir.net/termsofuse).

\n

membership: Conceptual

combinationMethod: All of

characteristic

code: Defined by CodeableConcept

value: Patients with mild COVID19 upper respiratory tract infection and with no evidence of pneumonia

exclude: false

description:

Patients with mild COVID19 upper respiratory tract infection and with no evidence of pneumonia

\n

characteristic

code: Defined by CodeableConcept

value: Adult (18 Years and above)

exclude: false

description:

Adult (18 Years and above)

\n

characteristic

code: Defined by CodeableConcept

value: Written informed consent prior to initiation of any study procedures by the patient (or legally authorized representative).

exclude: false

description:

Written informed consent prior to initiation of any study procedures by the patient (or legally authorized representative).

\n

characteristic

code: Defined by CodeableConcept

value: Understands and agrees to comply with planned study procedures.

exclude: false

description:

Understands and agrees to comply with planned study procedures.

\n

characteristic

code: Defined by CodeableConcept

value: Has laboratory-confirmed novel coronavirus (SARS-CoV-2) infection as determined by polymerase chain reaction (PCR) available at KAUH.

exclude: false

description:

Has laboratory-confirmed novel coronavirus (SARS-CoV-2) infection as determined by polymerase chain reaction (PCR) available at KAUH.

\n

characteristic

code: Defined by CodeableConcept

value: Patients with pneumonia or severe illness requiring admission to ICU.

exclude: true

description:

Patients with pneumonia or severe illness requiring admission to ICU.

\n

characteristic

code: Defined by CodeableConcept

value: Severe chronic kidney disease (i.e. estimated glomerular filtration rate (eGFR) \\< 30) or end stage renal disease requiring dialysis

exclude: true

description:

Severe chronic kidney disease (i.e. estimated glomerular filtration rate (eGFR) < 30) or end stage renal disease requiring dialysis

\n

characteristic

code: Defined by CodeableConcept

value: Sever chronic liver disease (Alanine transaminase/aspartate transaminase (ALT/AST) \\> 5 times the upper limit of normal).

exclude: true

description:

Sever chronic liver disease (Alanine transaminase/aspartate transaminase (ALT/AST) > 5 times the upper limit of normal).

\n

characteristic

code: Defined by CodeableConcept

value: Pregnancy or breast feeding.

exclude: true

description:

Pregnancy or breast feeding.

\n

characteristic

code: Defined by CodeableConcept

value: Anticipated transfer to another hospital which is not a study site within 72 hours.

exclude: true

description:

Anticipated transfer to another hospital which is not a study site within 72 hours.

\n

characteristic

code: Defined by CodeableConcept

value: Allergy to any study medication.

exclude: true

description:

Allergy to any study medication.

\n
" }, "extension" : [{ "url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status", "valueCodeableConcept" : { "coding" : [{ "system" : "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type", "code" : "active", "display" : "Active" }] } }, { "url" : "http://hl7.org/fhir/StructureDefinition/artifact-author", "valueContactDetail" : { "name" : "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter" } }, { "url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/cite-as", "valueMarkdown" : "NCT04401202 Eligibility Criteria [Database Entry: FHIR Group Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 189713. Revised 2026-08-05. Available at: https://fevir.net/resources/Group/189713. Computable resource at: https://fevir.net/resources/Group/189713#json." }], "url" : "https://fevir.net/resources/Group/189713", "identifier" : [{ "type" : { "coding" : [{ "system" : "http://terminology.hl7.org/CodeSystem/v2-0203", "code" : "ACSN", "display" : "Accession ID" }], "text" : "FEvIR Object Identifier" }, "system" : "https://fevir.net/FOI", "value" : "189713", "assigner" : { "display" : "Computable Publishing LLC" } }, { "type" : { "text" : "FEvIR Linking Identifier" }, "system" : "https://fevir.net/FLI", "value" : "NCT04401202 Eligibility Criteria", "assigner" : { "display" : "Computable Publishing LLC" } }], "name" : "NCT04401202_Eligibility_Criteria", "title" : "NCT04401202 Eligibility Criteria", "status" : "active", "publisher" : "Computable Publishing LLC", "contact" : [{ "telecom" : [{ "system" : "email", "value" : "support@computablepublishing.com" }] }], "description" : "Inclusion Criteria:\n* Patients with mild COVID19 upper respiratory tract infection and with no evidence of pneumonia\n* Adult (18 Years and above)\n* Written informed consent prior to initiation of any study procedures by the patient (or legally authorized representative).\n* Understands and agrees to comply with planned study procedures.\n* Has laboratory-confirmed novel coronavirus (SARS-CoV-2) infection as determined by polymerase chain reaction (PCR) available at KAUH.\nExclusion Criteria:\n* Patients with pneumonia or severe illness requiring admission to ICU.\n* Severe chronic kidney disease (i.e. estimated glomerular filtration rate (eGFR) \\< 30) or end stage renal disease requiring dialysis\n* Sever chronic liver disease (Alanine transaminase/aspartate transaminase (ALT/AST) \\> 5 times the upper limit of normal).\n* Pregnancy or breast feeding.\n* Anticipated transfer to another hospital which is not a study site within 72 hours.\n* Allergy to any study medication.", "copyright" : "Copyright the Authors else Computable Publishing LLC. Noncommercial use permitted with CC BY-NC-SA 4.0 (https://creativecommons.org/licenses/by-nc-sa/4.0/). Commercial use permitted as agreed in Terms of Use (https://fevir.net/termsofuse).", "membership" : "conceptual", "combinationMethod" : "all-of", "characteristic" : [{ "code" : { "text" : "Defined by CodeableConcept" }, "valueCodeableConcept" : { "text" : "Patients with mild COVID19 upper respiratory tract infection and with no evidence of pneumonia" }, "exclude" : false, "description" : "Patients with mild COVID19 upper respiratory tract infection and with no evidence of pneumonia" }, { "code" : { "text" : "Defined by CodeableConcept" }, "valueCodeableConcept" : { "text" : "Adult (18 Years and above)" }, "exclude" : false, "description" : "Adult (18 Years and above)" }, { "code" : { "text" : "Defined by CodeableConcept" }, "valueCodeableConcept" : { "text" : "Written informed consent prior to initiation of any study procedures by the patient (or legally authorized representative)." }, "exclude" : false, "description" : "Written informed consent prior to initiation of any study procedures by the patient (or legally authorized representative)." }, { "code" : { "text" : "Defined by CodeableConcept" }, "valueCodeableConcept" : { "text" : "Understands and agrees to comply with planned study procedures." }, "exclude" : false, "description" : "Understands and agrees to comply with planned study procedures." }, { "code" : { "text" : "Defined by CodeableConcept" }, "valueCodeableConcept" : { "text" : "Has laboratory-confirmed novel coronavirus (SARS-CoV-2) infection as determined by polymerase chain reaction (PCR) available at KAUH." }, "exclude" : false, "description" : "Has laboratory-confirmed novel coronavirus (SARS-CoV-2) infection as determined by polymerase chain reaction (PCR) available at KAUH." }, { "code" : { "text" : "Defined by CodeableConcept" }, "valueCodeableConcept" : { "text" : "Patients with pneumonia or severe illness requiring admission to ICU." }, "exclude" : true, "description" : "Patients with pneumonia or severe illness requiring admission to ICU." }, { "code" : { "text" : "Defined by CodeableConcept" }, "valueCodeableConcept" : { "text" : "Severe chronic kidney disease (i.e. estimated glomerular filtration rate (eGFR) \\< 30) or end stage renal disease requiring dialysis" }, "exclude" : true, "description" : "Severe chronic kidney disease (i.e. estimated glomerular filtration rate (eGFR) \\< 30) or end stage renal disease requiring dialysis" }, { "code" : { "text" : "Defined by CodeableConcept" }, "valueCodeableConcept" : { "text" : "Sever chronic liver disease (Alanine transaminase/aspartate transaminase (ALT/AST) \\> 5 times the upper limit of normal)." }, "exclude" : true, "description" : "Sever chronic liver disease (Alanine transaminase/aspartate transaminase (ALT/AST) \\> 5 times the upper limit of normal)." }, { "code" : { "text" : "Defined by CodeableConcept" }, "valueCodeableConcept" : { "text" : "Pregnancy or breast feeding." }, "exclude" : true, "description" : "Pregnancy or breast feeding." }, { "code" : { "text" : "Defined by CodeableConcept" }, "valueCodeableConcept" : { "text" : "Anticipated transfer to another hospital which is not a study site within 72 hours." }, "exclude" : true, "description" : "Anticipated transfer to another hospital which is not a study site within 72 hours." }, { "code" : { "text" : "Defined by CodeableConcept" }, "valueCodeableConcept" : { "text" : "Allergy to any study medication." }, "exclude" : true, "description" : "Allergy to any study medication." }] }